Jazz Pharmaceuticals
JAZZ
345 hedge funds and large institutions have $7.92B invested in Jazz Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 129 increasing their positions, 132 reducing their positions, and 61 closing their positions.
6% more capital invested
Capital invested by funds: $7.5B → $7.92B (+$423M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
2% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 132
4% less funds holding
Funds holding: 360 → 345 (-15)
23% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 61
24% less call options, than puts
Call options by funds: $86.7M | Put options by funds: $115M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
+$95.2M |
| 2 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$40.3M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$40.3M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$37.9M |
| 5 |
PC
PointState Capital
New York
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WBC
Westpac Banking Corp
Sydney,
Australia
|
-$238M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$30.3M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$28.5M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$27M |
| 5 |
Goldman Sachs
New York
|
-$25.4M |
JAZZ Hedge Fund Activity: Q4 2015 in Review
345 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2015, worth a combined $7.92B — up 5.6% from $7.5B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of JAZZ and 47 opened new positions — a net loss of 14 holders — while 132 trimmed existing stakes and 129 added.
The largest buyer was Herndon Capital Management, adding an estimated $95.2M. The largest seller was Westpac Banking Corp, cutting an estimated $238M.
- 345 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2015, down from 360 in Q3 2015.
- Funds reported $7.92B of Jazz Pharmaceuticals stock for Q4 2015, up 5.6% quarter-over-quarter.
- 47 funds opened new Jazz Pharmaceuticals positions in Q4 2015 and 61 closed out, a net change of -14 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2015 was Herndon Capital Management, an estimated $95.2M added.
- The largest Jazz Pharmaceuticals seller in Q4 2015 was Westpac Banking Corp, an estimated $238M sold.
Based on aggregated 13F filings for Q4 2015.